BPI Recombinant Rabbit Monoclonal Antibody (SN06-63), Invitrogen™

Description

• Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems
• The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits
• Then, individual clones are screened to select the best candidates for production
• The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire
• The antimicrobial protein BPI is a 55 kDa protein found in the primary (azurophilic) granules of human neutrophils and has also been detected on surface of neutrophils, small intestinal and oral epithelial cells
• BPI is a bactericidal compound that is present in polymorphonuclear cells (PMN) and in lower levels in the specific granules of eosinophils
• BPI possesses high affinity toward the lipid A region of lipopolysaccharides (LPS) that comprise the outer leaflet of the gram-negative bacterial outer membrane
• The binding of BPI to lipid A causes multiple anti-infective activities against gram-negative bacteria
• These include: cytotoxicity via sequential damage to bacterial outer and inner lipid membranes, neutralization of gram-negative bacterial LPS, opsonization of bacteria to enhance phagocytosis by neutrophils
• BPI may be a critical determinant in the development of LPStriggered airways disease since airway epithelial cells constitutively express the BPI gene and produce the BPI protein
• Inflammation induced by LPS possibly contributes to the development of rapid airflow decline, a serious and often fatal complication of hematopoietic cell transplantation
• Furthermore, a 21 kDa bioactive recombinant fragment of BPI, rBPI21, was shown to confer a survival advantage against invasive pneumococcal disease by binding to the gram-positive bacterial pathogen, pneumolysin.